Overcoming monocarboxylate transporter 8 (MCT8)-deficiency to promote human oligodendrocyte differentiation and myelination

Young Lee, J, Kim, M, Deliyanti, D, Azari, M, Rossello, F, Costin, A, Ramm, G, Stanley, E, Elefanty, A, Wilkinson-Berka, J and Petratos, S 2017, 'Overcoming monocarboxylate transporter 8 (MCT8)-deficiency to promote human oligodendrocyte differentiation and myelination', EBioMedicine, vol. 25, pp. 122-135.


Document type: Journal Article
Collection: Journal Articles

Title Overcoming monocarboxylate transporter 8 (MCT8)-deficiency to promote human oligodendrocyte differentiation and myelination
Author(s) Young Lee, J
Kim, M
Deliyanti, D
Azari, M
Rossello, F
Costin, A
Ramm, G
Stanley, E
Elefanty, A
Wilkinson-Berka, J
Petratos, S
Year 2017
Journal name EBioMedicine
Volume number 25
Start page 122
End page 135
Total pages 14
Publisher Elsevier
Abstract Cell membrane thyroid hormone (TH) transport can be facilitated by the monocarboxylate transporter 8 (MCT8), encoded by the solute carrier family 16 member 2 (SLC16A2) gene. Human mutations of the gene, SLC16A2, result in the X-linked-inherited psychomotor retardation and hypomyelination disorder, Allan-Herndon-Dudley syndrome (AHDS). We posited that abrogating MCT8-dependent TH transport limits oligodendrogenesis and myelination. We show that human oligodendrocytes (OL), derived from the NKX2.1-GFP human embryonic stem cell (hESC) reporter line, express MCT8. Moreover, treatment of these cultures with DITPA (an MCT8-independent TH analog), up-regulates OL differentiation transcription factors and myelin gene expression. DITPA promotes hESC-derived OL myelination of retinal ganglion axons in co-culture. Pharmacological and genetic blockade of MCT8 induces significant OL apoptosis, impairing myelination. DITPA treatment limits OL apoptosis mediated by SLC16A2 down-regulation primarily signaling through AKT phosphorylation, driving myelination. Our results highlight the potential role of MCT8 in TH transport for human OL development and may implicate DITPA as a promising treatment for developmentally-regulated myelination in AHDS.
Subject Neurology and Neuromuscular Diseases
Cellular Nervous System
DOI - identifier 10.1016/j.ebiom.2017.10.016
Copyright notice © 2017 Elesvier BV
ISSN 2352-3964
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 6 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 1 times in Scopus Article | Citations
Altmetric details:
Access Statistics: 37 Abstract Views  -  Detailed Statistics
Created: Mon, 18 Dec 2017, 10:01:00 EST by Catalyst Administrator
© 2014 RMIT Research Repository • Powered by Fez SoftwareContact us